✉ Email this page to a colleague
« Back to Dashboard
AZD-8330 is an investigational drug.
There have been 33 clinical trials for AZD-8330. The most recent clinical trial was a Phase 3 trial, which was initiated on September 15th 2021.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Ovarian Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.
There are one hundred and sixteen US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for AZD-8330
|Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2||AstraZeneca||Phase 3|
|Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2||Botswana Ministry of Health||Phase 3|
|Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2||Botswana Harvard AIDS Institute Partnership||Phase 3|
Top disease conditions for AZD-8330
Top clinical trial sponsors for AZD-8330
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AZD-8330||⤷ Try a Trial||Organic compositions to treat beta-catenin-related diseases||Arrowhead Pharmaceuticals, Inc. (Pasadena, CA)||⤷ Try a Trial|
|AZD-8330||⤷ Try a Trial||Minimal volume reprogramming of mononuclear cells||Fate Therapeutics, Inc. (San Diego, CA)||⤷ Try a Trial|
|AZD-8330||⤷ Try a Trial||7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy||Oncoceutics, Inc. (Philadelphia, PA)||⤷ Try a Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|AZD-8330||Australia||AU2013208720||2032-01-09||⤷ Try a Trial|
|AZD-8330||Brazil||BR112014016870||2032-01-09||⤷ Try a Trial|
|AZD-8330||Canada||CA2860676||2032-01-09||⤷ Try a Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|